Home › Funds › LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA › LLY

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA position in LLY

ELI LILLY & CO · Health Care

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reported holding 75,984 shares of LLY (ELI LILLY & CO) in its Q3 2026 13F filing — a position valued at US$87.9M, representing 0.81% of its reported portfolio and ranking #31 among its reported holdings. LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed LLY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)75.98K sh
Reported value held$87.92M
Portfolio Weight0.81%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's LLY position evolved

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA first disclosed a stake in LLY in Q3 2023 at 7,380 shares (US$4.3M). The position peaked in Q3 2026 at 75,984 shares, worth US$87.9M. Across 13 filings, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA increased the stake 9 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 75,984 shares valued at US$87.9M — an increase of 16,204 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2024 (shares rose 7% over the following quarter), a 194% increase in Q1 2026 (shares rose 30% over the following quarter), a 53% increase in Q2 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.38K $4.28M New
Q4 2023 7.65K $4.94M Add
Q1 2024 7.26K $5.31M Reduce
Q2 2024 7.42K $6.99M Add
Q3 2024 7.20K $6.41M Reduce
Q4 2024 9.86K $7.96M Add
Q1 2025 10.07K $8.35M Add
Q2 2025 10.09K $7.86M Hold
Q3 2025 13.19K $10.83M Add
Q4 2025 13.32K $13.85M Add
Q1 2026 39.19K $36.82M Add
Q2 2026 59.78K $71.70M Add
Q3 2026 75.98K $87.92M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LLY and 13F data

LLY (ELI LILLY & CO) is a Health Care company. 36 other funds we track also report a position in LLY — the largest reported positions include LILLY ENDOWMENT INC (US$104.21B), Vanguard Group (US$88.09B), BlackRock Inc (US$81.01B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LLY

All LLY fund holders →

FAQ

How long has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA held LLY?

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed LLY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's current position in LLY?

As of Q3 2026, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA holds 75.98K shares of LLY (ELI LILLY & CO), valued at $87.92M, representing 0.81% of its reported portfolio and ranking #31.

Has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA been buying or selling LLY?

In the latest 13F filing (Q3 2026), LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA increased its position in LLY. The position peaked in Q3 2026 at 75.98K shares.

Which other funds hold LLY?

Other major institutional holders of LLY include LILLY ENDOWMENT INC, Vanguard Group, BlackRock Inc, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.